The ibogaine case report yields no DEA scheduling accommodation and no cleared expanded-access pathway within 12 weeks; cardiac-risk framing dominates any official response.

Ibogaine is currently a Schedule I substance in the US — the most restricted category, meaning the government considers it to have no accepted medical use and high abuse potential. One published patient story won't prompt the DEA (the US Drug Enforcement Administration) to loosen that classification, and the FDA won't open a formal compassionate-use program (a special pathway letting seriously ill patients try unapproved drugs) based on a single anecdote. Ibogaine's history of causing fatal heart problems gives regulators every reason to move slowly.

One anecdote doesn't move Schedule I. Ibogaine's fatality record gives us every reason to hold the line on controlled access.